GXI.DE Gerresheimer AG XETRA -17% intraday 26 Feb 2026: earnings will matter

GXI.DE stock fell to €15.42 on XETRA today, down -17.27% or -€3.22 intraday as markets price ahead of the company earnings release on 26 Feb 2026. Traders pushed volume to 951,174 shares versus a 50-day average near 287,940, signalling a sharp reaction to the results risk. We summarise the Q4 earnings setup, key ratios like PE 27.10 and EPS €0.68, and what investors should watch when the Gerresheimer AG report hits after the close.

Earnings preview: GXI.DE stock and Q4 timing

Gerresheimer announces results on 26 Feb 2026 after market close; the earnings call is scheduled for 16:30 UTC. Traders are focused on revenue guidance and margin drivers in Plastics & Devices and Primary Packaging Glass. One near-term claim: weak guidance could force another leg lower given high net debt and tight cash conversion metrics.

Market reaction and intraday price action for GXI.DE stock

Shares opened at €15.51, traded between €14.83 and €16.15, and closed intraday near €15.42 on heavy turnover. Volume of 951,174 equals about 3.31x the average daily volume, indicating distribution. The same-day drop of -€3.22 connects directly to sentiment ahead of the print and the wider healthcare sector softness in Germany today.

Fundamentals and valuation snapshot

Gerresheimer AG reports market cap €636,572,200.00, EPS €0.68, and trailing PE 27.10. Book value per share stands at €41.34, while price-to-book is 0.45, reflecting market de-rating versus balance sheet strength. Net debt metrics show enterprise value €2,801,270,200.00 and netDebt/EBITDA 5.48, highlighting leverage as a primary valuation risk.

Technical and volume snapshot for GXI.DE stock

Technicals show RSI 30.85, MACD negative and ADX 33.44 for a strong downtrend. Bollinger lower band sits at €16.17, below today’s close, and ATR is €1.37, indicating elevated volatility. High relative volume and negative on-balance volume confirm sellers dominated today, increasing the chance of follow-through before the earnings release.

Meyka AI rates GXI.DE with a score out of 100 and forecast

Meyka AI rates GXI.DE with a score out of 100: 66.44 (Grade B, Suggestion: HOLD). This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly €11.28 and quarterly €14.81, implying a -26.86% and -3.99% move versus the current price €15.42 respectively. Forecasts are model-based projections and not guarantees.

Risks, opportunities and analyst view

Key risks include high leverage with debt-to-equity 1.65, weak free cash flow per share -€2.51, and margin pressure in primary glass. Opportunities include product mix recovery in Advanced Technologies and pricing power in drug-delivery systems. Market consensus ratings are mixed; third-party scorecards showed a company rating of C+ on 24 Feb 2026 with a Sell bias, underlining divergent views.

Final Thoughts

Takeaways: GXI.DE stock trades at €15.42 after a -17.27% intraday move as investors position ahead of Gerresheimer AG’s earnings on 26 Feb 2026. The company shows solid book value €41.34 per share but carries elevated leverage and negative free cash flow per share -€2.51. Meyka AI’s forecast model projects €11.28 (monthly) and €14.81 (quarterly), implying -26.86% and -3.99% relative to today. For scenario planning we set price targets: conservative €12.00 (downside -22.18%), base €18.00 (upside +16.74%), bull €28.00 (upside +81.58%). These targets reflect balance-sheet risk, near-term earnings sensitivity, and optionality from advanced drug-delivery products. Use the earnings print and management guidance to re-weight risk; Meyka AI, an AI-powered market analysis platform, will update forecasts after the release. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.